The need for continued education is critical in these uncertain times. Therefore, the co-directors of the Fall Clinical Dermatology Conference are excited to announce our new program: the Fall Clinical Virtual Grand Rounds (FCVGR). This new online series is designed to help maintain the educational opportunities one would have if they were able to attend grand rounds in person.

FCVGR will consist of weekly CME sessions on a variety of dermatological diseases and tools.

This week, we will be coming to you LIVE!
Wednesday, July 22, 2020
8 PM EDT/ 5 PM PDT

EVOLVING CONCEPTS IN DERMATOLOGY PART XI

Updates on the Use of Anti-Interleukin-17 Agents in the Treatment of Psoriatic Disease

Reactivating Your Cosmetic Practice in the COVID Era: Clinical Tips and New Options

Log in to Begin Activity

April Armstrong, MD, MPH

Faculty

Professor of Dermatology
Associate Dean of Clinical Research
University of Southern California
Los Angeles, CA

Susan Weinkle, MD

Faculty

Affiliate Clinical Professor of Dermatology
University of South Florida
Tampa, Florida

Upon completion of this activity, the participant should be better able to:

Describe the mechanism of action of IL-17 inhibitors
Describe the clinical relevance of the IL-17 agents with an emphasis on safety and efficacy
Discuss the current societal and clinical impact of COVID 19 and how to safely re-open your dermatological cosmetic practice
Describe three CDC guidelines for mitigating COVID risks in your dermatology practice

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and the Foundation for Research and Education in Dermatology. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

The Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from Almirall, Bristol-Myers Squibb, Lilly, Mayne Pharma, and UCB.

CONFLICTS OF INTEREST/DISCLOSURES

April Armstrong, MD, MPH serves on advisory boards for Abbvie, Janssen, Lilly,Johnson, Leo Novartis, Ortho Dermatologics, Sanofi Genzyme Regeneron, Dermavant, and Modernizing Medicine, is a consultant for Abbvie, Janssen, Lilly,Johnson, Leo Novartis, Ortho Dermatologics, Sanofi Genzyme Regeneron, Dermavant, and Modernizing Medicine, receives grant research support from BMS, Dermira, Novartis, Sanofi Genzyme Regeneron, and UCB.

Susan H. Weinkle, MD serves on advisory boards for Allergan, Galderma, Revance, and Teoxane, and is a consultant for Allergan, Galderma, and Teoxane, and is on the speaker's bureau for Medscape.

Cathy Pagano (Institute for Continuing Healthcare Education) has disclosed that she has no relevant financial relationships specific to the subject matter within the past 12 months.

Session 14 Evolving Concepts in Dermatology Part XI

April Armstrong, MD, MPH

Susan Weinkle, MD

CONFLICTS OF INTEREST/DISCLOSURES

Session 14
Evolving Concepts in Dermatology Part XI